Altoprev (lovastatin extended-release formulation) / Shionogi, AbbVie - LARVOL DELTA

Lipid Management in Renal Transplant Recipients Using Evolocumab. (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Dyslipidemia • Transplantation

Enhanced method for extraction and analysis of statin drugs in fish tissue (ACS-Sp 2023) - "Between January 1, 2002 and December 31, 2018, an average of 21.35 million doses of statins were purchased annually in the United States with atorvastatin (Lipitor®), rosuvastatin (Crestor®), simvastatin (Zocor®), lovastatin (Mevacor® and Altoprev®), and pravastatin (Pravachol®) representing some the most commonly prescribed statins. Preliminary results demonstrate a 93.9% and 70.1% recovery for atorvastatin and simvastatin, respectively, with an 86.5% recovery achieved for the extraction standard, mevastatin. These results provide the preliminary foundation for future evaluations of the statins environmental health burden on fish populations."

Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure

Lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Comparison table: Some lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Lipid Management in Renal Transplant Recipients Using Evolocumab. (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Dyslipidemia • Transplantation

Lipid Management in Renal Transplant Recipients Using Evolocumab. (clinicaltrials.gov) - P4; N=120; Recruiting; Sponsor: Brigham and Women's Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dyslipidemia • Transplantation

Lipid Management in Renal Transplant Recipients Using Evolocumab. (clinicaltrials.gov) - P4; N=120; Not yet recruiting; Sponsor: Brigham and Women's Hospital

Clinical • New P4 trial • Dyslipidemia • Renal Disease • Transplantation

"Only two in the common list: atorvastatin (Lipitor), fluvastatin (Lescol XL), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor, Ezallor) and simvastatin (Zocor, FloLipid)?" (@niftymitch)

Bempedoic acid (Nexletol) for lowering LDL-cholesterol. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

RNA Sequencing Reveals Therapeutic Effects of Multiple Statins on Pancreatic Cancer Cells (APA 2016) - "Methods: The aim of this study was to determine the anti-cancer effects and to evaluate their therapeutic potentials of the three statins (fluvastatin, lovastatin, and simvastatin) on human PC cell lines MiaPaCa2 and PANC1. Taken together, these results demonstrated the anti-cancer effects of statins at high doses on the human PC cells was via the inhibition of cell proliferation gene expression. Statin treatment may provide a novel therapeutic choice for PC."

Biosimilar • Cardiovascular • Dyslipidemia • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

LovaMiX: Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome (clinicaltrials.gov) - P2; N=26; Not yet recruiting; Sponsor: Université de Sherbrooke

New P2 trial • Biosimilar

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Luye Pharma Group Ltd.; Recruiting ➔ Completed

Trial completion • Biosimilar • Small Cell Lung Cancer

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Luye Pharma Group Ltd.

New P1 trial • Biosimilar

Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans. (PubMed) - "Published data from intravascular ultrasound studies (IVUS) was used in this work to develop and validate a unique integrative system model; this consisted of analyzing control groups from two randomized controlled statins trials (24/97 subjects respectively), one treated group (40 subjects, simvastatin trial), and 27 male subjects (simvastatin, pharmacokinetic study). The model allows to simulate the pharmacokinetics of statins and its effect on the dynamics of lipoproteins (e.g., LDL) and the inflammatory pathway while simultaneously exploring the effect of flow-related variables (e.g., wall shear stress) on atherosclerosis progression."

Journal • Atherosclerosis • Biosimilar • Dyslipidemia • Immunology • Inflammation

The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care. (PubMed) - J Clin Pharm Ther - "Overall, 27·6% of patients with dyslipidaemia, including 30% of the HR group, did not achieve LDL-C treatment goals, despite on LLT. Addressing their concerns and adjusting medication doses of their LLT are needed for better outcomes."

Journal • Acute Coronary Syndrome • Biosimilar • Cardiovascular • Dyslipidemia

Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice. (PubMed) - Acta Pharmacol Sin - "Isoflavones and phytosterols in XZK exert cholesterol-lowering effects in HFD mice through mechanisms that differ from those of lovastatin. Isoflavones and phytosterols act in a complimentary manner: through enhancing the elimination of bile acids and reducing intestinal cholesterol absorption, respectively."

Journal • Biosimilar • Dyslipidemia

Restoration of Physiologically Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient Induced Pluripotent Stem Cells. (PubMed) - "FH-MC-LDLR demonstrated a physiological response, with virtually no DiI-LDL internalization with excess sterols and an ~2-fold increase in DiI-LDL internalization by Lovastatin compared to FH-MC. These findings demonstrate the feasibility of functionalizing genetically deficient iPSC using episomal plasmids to deliver physiologically responsive transgenes."

Journal • Biosimilar • Dyslipidemia

Lovastatin, but not orlistat, reduces intestinal polyp volume in an ApcMin/+ mouse model. (PubMed) - Oncol Rep - "In the mice receiving orlistat, we observed a significant increase in cell proliferation in the polyp tissue, as well as enhanced expression of ERα. Moreover, the overexpression of ERα was associated with a statistically significant increase in PES1, Shh and Gli1 protein levels, considered ERα-related molecular targets."

Journal • Biosimilar

Human Vascular Microphysiological System for in vitro Drug Screening. (PubMed) - Sci Rep - "Treatment of TEBVs with 1 μM lovastatin for three days prior to addition of Tumor necrosis factor - α (TNF-α) blocked the injury response and maintained vasodilation. These results indicate the potential to develop a rapidly-producible, endothelialized TEBV for microphysiological systems capable of producing physiological responses to both pharmaceutical and immunological stimuli."

Journal • Biosimilar

Environmental cues that induce the physiology of solid medium: a study on lovastatin production by Aspergillus terreus. (PubMed) - J Appl Microbiol - "This knowledge is the starting point to investigate how these environmental cues are sensed and transduced, impacting secondary metabolites and enzyme production. These results have important applied potential in new strategies to generate overproducing strains, as well as application in the design of novel production systems."

Journal • Biosimilar

Complete Genome Sequence of the Endophytic Fungus Diaporthe (Phomopsis) ampelina. (PubMed) - Genome Announc - "The whole genome is 59 Mb, contains a total of 905 scaffolds, and has a G+C content of 51.74%. The genome sequence of D. ampelina shows a complete absence of lovastatin (an anticholesterol drug) gene cluster."

Journal • Biosimilar

Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid-β Production in vivo and in vitro. (PubMed) - "Lovastatin modifies the mevalonate pathway without affecting cholesterol levels in vivo and is able to reduce Aβ levels only in vitro."

Journal • Alzheimer's Disease • Biosimilar • Oncology

Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein. (PubMed) - "This proof-of-concept study demonstrated that AA-LT-d-rHDL could enhance drug accumulation in atherosclerotic lesion and impede atherosclerosis progression more effectively."

Journal • Atherosclerosis • Biosimilar • Dyslipidemia • Immunology • Inflammation

Purification of Lovastatin from Aspergillus terreus (KM017963) and Evaluation of its Anticancer and Antioxidant Properties. (PubMed) - Asian Pac J Cancer Prev - "Cell cycle analysis by ow cytometry (propidium iodide staining) confirmed induction of apoptotic cell death and revealed cell cycle arrest in the G0/G1 phase. The results of the study give leads for the anticancer effects of lovastatin and its potential usefulness in the chemotherapy of cervical cancer."

Journal • Biosimilar • Cervical Cancer • Oncology

Lovastatin induces neuroprotection by inhibiting inflammatory cytokines in 6-hydroxydopamine treated microglia cells. (PubMed) - "Our results suggest that Lovastatin is able to induce neuroprotection by inhibiting inflammatory cytokines. The data provide direct evidence of the potential application of lovastatin for the treatment of neuroinflammatory diseases."

Journal • Biosimilar • Immunology • Inflammation